logo
Yahoo

Yahoo

Yahoo8 hours ago

There are conflicting opinions on how often a person should wash their hair — and two experts are setting the record straight.
Considering NYC is in the dog days of summer and pollen is still floating around in the air — Dr. Pallavi Bradshaw, Deputy Chief Medical Officer at AXA Health Insurance, told the Daily Mail that people should be washing their hair every day.
Before you fret, claiming that sudsing up daily is bad for your hair — Bradshaw has good reason for his claim. Experts say hair should be washed daily to get rid of pollen and sweat. rh2010 – stock.adobe.com
If you're someone who suffers from pollen allergies — which is still present in the summer, not just the spring — Bradshaw says to shower daily using 'warm water rather than hot… to avoid drying out the skin and, where possible, use hypoallergenic soaps or shampoos.'
And if a stuffy nose isn't getting you down, but you're strands are slick thanks to the scorching hot temperatures swallowing the Northeast right now — Mandy (B.) Buechner, a certified trichologist and hair loss practitioner, told Yahoo! that daily hair washing is recommended in the summer.
'You want to keep your scalp as clean and clear as possible for healthier hair growth. Think of your scalp care as skin care,' she told the outlet.
'I always recommend not going longer than three days without washing your hair all year round, however, in the summer, if you are swimming or sweat a lot, you can safely wash every day or every other day as needed.'
One of the major concerns people have when they're told to wet their strands every day is the possibility of drying out their hair.
To combat this, Buechner recommends using moisturizing hair care products. Experts say to treat scalp care like skin care. Mikhail Ulyannikov – stock.adobe.com
'These have essential lipids in the formula to restore moisture and hydration lost during harsh hot summer months.'
And if you plan to spend an ample amount of time outside this season, the sun's UV rays can be damaging to any hair type, so it's recommended to protect your locks by wearing a hat and using SPF on your scalp — since it can burn if exposed.
Speaking of hair, if you notice yours is on the thinning side these days — which is very normal, considering 80% of men and nearly half of women experience hair loss, according to NYU Langone experts say several different treatments on the market are effective.
'There are several effective treatments available for hair loss, and the best approach depends on an individual's specific diagnosis and needs, which should be thoroughly reviewed with a dermatologist,' Dr. Brian Abittan, Director of Skin and Hair Rejuvenation and Director of Hair Transplantation at the Kimberly and Eric J. Waldman Department of Dermatology at Mount Sinai, told The Post.
A few of them include minodixil, finasteride and redensyl.
'Minodixil helps stimulate hair growth,' Manhattan board-certified dermatologist Dr. Dina Strachan said.
'Finasteride has been shown to slow hair loss and even regrow hair in some cases, but it carries a low risk of side effects, including erectile dysfunction, reduced sperm count and, less commonly, depression,' said Abittan.
'Redensyl stimulates hair growth,' said Strachan. However, she did warn that this treatment can cause irritation and dandruff.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mosquitos in Northern Colorado county test positive for West Nile virus
Mosquitos in Northern Colorado county test positive for West Nile virus

CBS News

timean hour ago

  • CBS News

Mosquitos in Northern Colorado county test positive for West Nile virus

This week, a sample of the mosquito population in Larimer County in Northern Colorado tested positive for West Nile virus. County health officials say this marks the beginning of heightened risk for residents, as warmer weather and rain lead to more mosquito activity. About 1 in 5 people infected may develop flu-like symptoms, including fever, headaches, body aches, fatigue, vomiting, diarrhea, and rash. About 1 in 150 people who are infected develop more severe illness, which includes symptoms of high fever, headache, tremors, muscle weakness, vision loss and paralysis. Mosquitos in Larimer County have tested positive for West Nile Virus. CBS When Lisa Montez visited Fort Collins in the summer of 2022, she never imagined a mosquito bite would turn her life upside down. What started as mild fatigue turned into a months-long ordeal that left her unable to drive, plagued by chronic fatigue, and permanently impacted by the bite. "The next day, I woke up and was very, very tired. But I figured, because I was traveling and we were with family, that it was just a normal vacation tied," Montez said. She returned home to Washington. Within days, Montez broke out in a full-body rash. Doctors initially suspected something minor - maybe an ear infection or just a viral bug. But despite multiple visits to urgent care and emergency rooms, her condition worsened with no clear answers. It took two months and a battery of tests before doctors finally diagnosed her with West Nile virus. Montez, a healthy woman in her 30s, ended up with a rare neuroinvasive form of the illness. CBS Colorado's Tori Mason walks with Lisa Montez. CBS "My husband was doing everything on his own. I couldn't do laundry, I couldn't cook, I couldn't clean. A lot of times I was just in bed because I was so dizzy or I was so tired," she explained. She wasn't able to drive a car for about a year. Her family returned to Colorado to get support from family and treatment at UCHealth. Montez was in vestibular rehab for 11 months and in occupational therapy for eight months. "I think that had we not come back, I wouldn't be where I am, and I wouldn't have progressed as far as I have through this with the support that I had. So I'm very grateful for UCHealth and for all of the time that they invested," she said. People ages 55 and older are at higher risk of serious symptoms if they get West Nile virus. People with health conditions such as cancer, diabetes, and hypertension, and who have had organ transplants or are taking medications that suppress the immune system, are also at risk. There are no vaccines to prevent West Nile virus. Dr. Bob Belknap, Director of the Public Health Institute at Denver Health, says if people have it, it's supportive care. "If someone is feeling sick, and if they have any concern at all, we recommend that they seek medical care. Do not hesitate. People usually know if something is mild and it's manageable, something they can treat with over-the-counter medications," he said. "If it's at all concerning, or if it's getting worse despite those treatments, then definitely people should seek care." Larimer County CBS The Health Department urges all residents to adopt effective protective measures as part of their summer routine: Regularly use an EPA-registered insect repellent. Wear loose-fitting long-sleeved shirts and pants for long walks, gardening, and other times outside. Avoid outdoor activities during peak biting times around dawn and dusk. Montez says the experience completely reshaped how she approaches outdoor activities. She hopes her experience reminds others not to brush off those bites. "I have nerve damage in my body. My left side was impacted more than the rest of my body, so I have weakness in the left side of my body. I actually have a little bit of drooping in this side of the face," she said. "I'm better today, but I will have lifelong effects from this."

Guselkumab Clears Scalp Psoriasis Across Skin Tones
Guselkumab Clears Scalp Psoriasis Across Skin Tones

Medscape

timean hour ago

  • Medscape

Guselkumab Clears Scalp Psoriasis Across Skin Tones

TOPLINE: In the VISIBLE trial, guselkumab led to significant and sustained improvements in scalp psoriasis severity and quality of life in patients with skin of color through 48 weeks. METHODOLOGY: Researchers evaluated outcomes in a cohort of patients in the phase 3b randomized VISIBLE trial, which included 102 adults with skin of color and scalp psoriasis (mean age, 42.5 years; Fitzpatrick skin type IV-VI, 62.7%; 56.9% men) at 45 sites in the US and Canada from September 2022 to June 2024. Participants self-identified as Asian (38.2%), non-White Hispanic or Latino (38.2%), Black (10.8%), and Middle Eastern (4.9%). Participants were randomly assigned 3:1 to receive guselkumab or placebo with crossover to guselkumab at week 16. Coprimary endpoints were scalp-specific Investigator's Global Assessment (ss-IGA) score of 0/1 and 90% improvement in Psoriasis Scalp Severity Index (PSSI) at week 16. Secondary outcomes were changes in PSSI, scalp surface area, Dermatology Life Quality Index (DLQI), Scalp Itch Numeric Rating Scale, Psoriasis Symptoms and Signs Diary, and complete clearance. TAKEAWAY: At week 16, patients treated with guselkumab showed significantly higher response rates than those with placebo for ss-IGA 0/1 (68.4% vs 11.5%; P < .001) and PSSI 90 (65.8% vs 3.8%; P < .001). Complete scalp clearance was higher in the guselkumab group: ss-IGA 0 (57.9% vs 3.8%; P < .001) and PSSI 100 (59.2% vs 3.8%; P < .001). At week 16, guselkumab led to greater mean percentage improvements in PSSI (least squares mean [LSM] change, 87.6% vs 37.8%; P < .001) and scalp surface area (SSA; LSM change, 86.6% vs 33.4%; P < .001). Patients reported improved quality of life (DLQI: LSM change, -9.7 vs -2.2; P < .001), symptom relief (LSM change, -44.8 vs -8.3; P < .001), and improvements in itch scores (69.4% vs 24.0%; P < .001) with guselkumab vs placebo at week 16. Over 90% of patients achieved mean percentage improvements with guselkumab in PSSI and SSA by week 48, with 67.1% achieving complete scalp clearance (ss-IGA 0). One patient in the placebo group experienced at least one serious adverse event (SAE) at week 16 vs none in the guselkumab-treated group. From 0-48 weeks, at least one SAE was reported in 2.5% of patients on guselkumab; no adverse events resulted in drug discontinuation. IN PRACTICE: The findings showed that 'guselkumab is highly effective for the treatment of moderate-to-severe scalp psoriasis in individuals with skin of color across the spectrum of objectively measured skin tones,' the study authors concluded. SOURCE: This study was led by Amy McMichael, MD, Wake Forest University School of Medicine, Winston-Salem, North Carolina, and was published online on June 25 in JAMA Dermatology. LIMITATIONS: Postinflammatory pigment alteration, a common concern in people with skin of color, was not fully captured. DISCLOSURES: Johnson & Johnson provided funding support for this study. McMichael reported receiving personal fees, nonfinancial support, and royalties from various organizations, including Johnson & Johnson. Several other authors also reported receiving personal fees, investigator fees, salary, stock, and stock options from Johnson & Johnson and multiple other companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store